Barclays has initiated coverage on Zoetis Inc (ZTS) with an Equal-Weight rating, marking the firm's first assessment of the company. This decision reflects Barclays' analysis of Zoetis' business, industry dynamics, and growth prospects.
Headquartered in Parsippany, New Jersey, Zoetis engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products for animal health. The company operates through two segments: the United States and International, offering a diverse portfolio that includes parasiticides, vaccines, and diagnostics for both companion animals and livestock. With a market cap of $56.5 billion, Zoetis currently has a P/E ratio of 21.31 and an EPS of 5.94.
Investors can expect upcoming earnings reports, with estimates of $1.88 EPS and $2.6 billion in revenue for August 3, 2026, and $1.58 EPS with $2.3 billion in revenue expected on May 4, 2026. Analyst consensus as of December 1, 2025, shows a majority rating of Buy, with 7 Strong Buy, 11 Buy, and 6 Hold ratings among 24 total analysts.
This update provides insight into how analyst ratings can serve as one of many factors in investment decisions, reflecting professional opinions based on research and financial models. As always, it is essential for investors to consider various elements, including company fundamentals and industry trends, when evaluating investment opportunities.